COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,641 Articles (22,913 medRxiv, 8,728 bioRxiv)

Most recent first Previous |  Page 1653: Articles 16521-16530  | Next

Strong anti-viral responses in pediatric COVID-19 patients in South Brazil
Fazolo, T., Lima, K., Fontoura, J. C., Souza, P. O. d., Hilario, G., Zorzetto, R., Rodrigues, L., Pscheidt, V. M., Ferreira Neto, J., Haubert, A. F., Gambin, I., Oliveira, A. C., Mello, R. S., Gutierrez, M., Gassen, R. B., Sauthier Sartor, I. T., Zavaglia, G. O., Fernandes, I. R., Varela, F. H., Polese-Bonatto, M., Borges, T. J., Callegari-Jacques, S. M., da Costa, M. S. C., Schwartz, J. d. A., Scotta, M. C., Stein, R. T., Bonorino, C.
10.1101/2021.04.13.21255139 — Posted: 2021-04-16
Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation
Serra, A., Fratello, M., Federico, A., Ojha, R., Provenzani, R., Tasnadi, E., Cattelani, L., del Giudice, G., Kinaret, P. A. S., Saarimaki, L. A., Pavel, A., Cerullo, V., Vapalahti, O., Horvath, P., Di Lieto, A., Yli-Kauhaluoma, J., Balistreri, G., Greco, D.
10.1101/2021.04.15.440004 — Posted: 2021-04-15
Time-series trend of pandemic SARS-CoV-2 variants visualized using batch-learning self-organizing map for oligonucleotide compositions
Abe, T., Furukawa, R., Iwasaki, Y., Ikemura, T.
10.1101/2021.04.15.439956 — Posted: 2021-04-15
Multi-modal engineering of Bst DNA polymerase for thermostability in ultra-fast LAMP reactions
Paik, I., Ngo, P. H. T., Shroff, R., Maranhao, A. C., Walker, D. J. F., Bhadra, S., Ellington, A.
10.1101/2021.04.15.439918 — Posted: 2021-04-15 Discussion: Onsite
Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor binding domain in engineered Komagataella phaffii
Dalvie, N. C., Biedermann, A. M., Rodriguez-Aponte, S. A., Naranjo, C. A., Rao, H. D., Rajurkar, M. P., Lothe, R. R., Shaligram, U. S., Johnston, R. S., Crowell, L. E., Castelino, S., Tracey, M. K., Whittaker, C. A., Love, J. C.
10.1101/2021.04.15.440035 — Posted: 2021-04-15
Evaluation of the SARS-CoV-2 inactivation efficacy associated with buffers from three kits used on high-throughput RNA extraction platforms
Thom, R. E., Eastaugh, L., O'Brien, L., Ulaeto, D., Findlay, J. S., Smither, S., Phelps, A., Stapleton, H., Hamblin, K. A., Weller, S. A.
10.1101/2021.04.14.439928 — Posted: 2021-04-15
SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8
Salvi, V., Nguyen, H. O., Sozio, F., Schioppa, T., Laffranchi, M., Scapini, P., Passari, M., Barbazza, I., Tiberio, L., Tamassia, N., Garlanda, C., Del Prete, A., Cassatella, M., Mantovani, A., Sozzani, S., Bosisio, D.
10.1101/2021.04.15.439839 — Posted: 2021-04-15
Distorted TCR repertoires define multisystem inflammatory syndrome in children
Malik, A., Toth, E. N., Teng, M. S., Hurst, J., Watt, E., Wise, L., Kent, N., Bartram, J., Grandjean, L., Dominguez-Villar, M., Adams, S., Cooper, N.
10.1101/2021.04.12.21255098 — Posted: 2021-04-15
Disparities in SARS-CoV-2 Vaccination-to-Infection Risk, Massachusetts 2020-2021
Dryden-Peterson, S., Velasquez, G. E., Stopka, T. J., Davey, S., Gandhi, R. T., Lockman, S., Ojikutu, B.
10.1101/2021.04.14.21255467 — Posted: 2021-04-15
Central obesity, smoking habit and hypertension are associated with a blunted serological response to COVID-19 mRNA vaccine
Watanabe, M., Balena, A., Tuccinardi, D., Tozzi, R., Risi, R., Masi, D., Caputi, A., Rossetti, R., Spoltore, M. E., Filippi, V., Gangitano, E., Manfrini, S., Mariani, S., Lubrano, C., Lenzi, A., Mastroianni, C., Gnessi, L.
10.1101/2021.04.13.21255402 — Posted: 2021-04-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).